A relatively large proportion of CML patients were found t(9;22) BCR-ABL p210 about 72.7% including two transcripts with the b3a2 (45.4%) and b2a2 (27.2%). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.